Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 mRNA vaccine prototype
- Development stage
- Preclinical
- Lead developer
- SINERGIUM Biotech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The H5N1 mRNA vaccine prototype is a preclinical-stage mRNA-based vaccine candidate being developed by Sinergium Biotech in collaboration with the Laboratory of Nucleic Acid Immunotechnology (LITAN) at the University of Buenos Aires-CONICET. The project is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization (WHO), the Medicines Patent Pool (MPP), and the Pan American Health Organization (PAHO). Designed as a flexible, 'plug-and-play' mRNA platform, the vaccine uses the H5N1 avian influenza virus (specifically clade 2.3.4.4b) as a prototype pathogen. It delivers genetic sequences encoding the H5N1 hemagglutinin (HA) and neuraminidase (NA) antigens, directing host cells to express these proteins and elicit a protective adaptive immune response. This initiative is part of the WHO/MPP mRNA Technology Transfer Programme, which aims to establish local mRNA vaccine manufacturing capacity and improve vaccine access and equity for manufacturers in low- and middle-income countries (LMICs).
- Other names
- H5N1 prototypeH-5N1 prototypeH 5N1 prototypemRNA vaccine platformmRNA vaccine platform (H5N1 prototype)Sinergium H5N1 mRNA vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)N1 NA (Influenza A neuraminidase N1)γδ TCR (T-cell receptor)HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on H5N1 mRNA vaccine prototype.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 mRNA vaccine prototype.